Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
Can Large Language Models Solve More Rare Disease Genomes?
LLM-assisted rare disease re-assessment improved genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.
Can Large Language Models Solve More Rare Disease Genomes?
LLM-assisted rare disease re-assessment improved genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.
How AI Is Reshaping Data Integrity in Pharma Manufacturing
Veragence CEO Nour AlSaleh discusses how AI is transforming data integrity in pharma manufacturing, regulatory compliance, the "human-in-the-loop" requirement, and patient safety in the era of AI-driven GxP systems.
What Drives Pharmaceutical R&D Success? New Benchmarking Reveals Why Some Drug Pipelines Outperform Others
Explore new benchmarking research on pharmaceutical R&D success rates, revealing why some drug pipelines consistently achieve higher approval rates than others.
The FDA’s 2026 gene editing draft guidance could change your regulatory strategy. Explore the new NGS requirements for cell and gene editing therapies.
ICH E6(R3) raises the governance bar for CRO and vendor oversight in clinical trials. Here's what sponsors must build into outsourcing relationships to protect trial quality and timelines.